May 1, 1989Journal of Clinical Oncology
Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.
Why the study?
Does adding doxorubicin to chemotherapy regimens improve disease-free survival and overall survival in women with stage II breast cancer?
Population
Women with primary breast cancer and positive axillary nodes, n=1,813.
Comparison
Doxorubicin added to melphalan and fluorouracil… vs Melphalan and fluorouracil for…
Design
RCT, Randomized between PFT and PAFT and between PF and PAF.
Follow-up
Through 6 years
Authors
Discussion
Loading...
Member takes
Implication
Supports adding doxorubicin to PF in tamoxifen-nonresponsive stage II breast cancer; extends evidence for anthracycline benefit in this subgroup.
Structured PICO
Does adding doxorubicin to chemotherapy regimens improve disease-free survival and overall survival in women with stage II breast cancer?
P
Population
Women with primary breast cancer and positive axillary nodes (stage II), n=1,813 (1,106 considered responsive to tamoxifen, 707 nonresponsive to tamoxifen).
I
Intervention
Doxorubicin added to melphalan and fluorouracil (PAF) for tamoxifen-nonresponsive patients, or added to melphalan, fluorouracil, and tamoxifen (PAFT) for tamoxifen-responsive patients.
C
Comparator
Melphalan and fluorouracil (PF) for tamoxifen-nonresponsive patients, or melphalan, fluorouracil, and tamoxifen (PFT) for tamoxifen-responsive patients.
O
Outcome
Disease-free survival (DFS) and survival.hard clinical
Adding doxorubicin to melphalan and fluorouracil improves disease-free and overall survival in tamoxifen-nonresponsive stage II breast cancer patients without significant cardiac toxicity.
Cite This Study
Fisher et al. (1989) studied this question.